Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice.

ABSTRACT: Antibodies have been explored extensively as a potential therapeutic for Alzheimer's disease, where amyloid-β (Aβ) peptides and the tau protein deposit in patient brains. While the major focus of antibody-based therapy development was on Aβ, arguably with limited success in clinical trials, targeting tau has become an emerging strategy, possibly extending therapies to dementias with isolated tau pathology. Interestingly, low titres of autoantibodies to pathological tau have been described in humans and transgenic mouse models, but their pathophysiological relevance remained elusive. Here, we used two independent approaches to deplete the B-cell lineage and hence antibody formation in human P301S mutant tau transgenic mice, TAU58/2. TAU58/2 mice were either crossed with the B-cell-deficient

SUBMITTER: van der Hoven J 

PROVIDER: S-EPMC7428012 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature